RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
No new studies have been requested
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Building the future of food in the birthplace of cell-cultured milk
Data published in the prestigious journal ACS Central Science of the American Chemical Society
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
Recall does not include any metabolic deficiency nutrition formulas
Subscribe To Our Newsletter & Stay Updated
